Nephrocare Shares Dip 4% Post-Listing, Still Above IPO Price

• Nephrocare Health Services shares debuted on December 17 at Rs 490 on NSE, a 6.52% premium over its Rs 460 IPO price.
• Despite a premium listing, shares fell 4% post-debut, closing at Rs 471.60, which is still 2.5% higher than the IPO price.
• The Rs 871-crore IPO, under the Nephroplus brand, saw strong investor interest, subscribed 14 times between December 10-12.
• Prior to listing, grey market premium (GMP) estimates ranged from 8.04% to 8.69% over the IPO price.
• Experts note long-term growth potential from rising kidney disease and expansion, but advise caution on margin sustainability and regulatory factors.

Why It Matters: Nephrocare shares saw a premium listing but closed lower, yet remain above IPO price amid strong investor interest.